^
Association details:
| Biomarker: | BCR-ABL1 V299L |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Treatment options based on BCR-ABL1 mutation profile…Dasatinib…Contraindicated mutations...T315I/A, F317L/V/I/C, or V299L
Source:
Title:
Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study
Published date:
11/01/2018
Excerpt:
Most importantly, NGS provided a more accurate picture of BCR-ABL1 mutations status in 40 (46%) pts who turned out to have one or more low burden mutations in addition to the dominant mutation(s) detectable by Sanger seq….in 4 pts where Sanger seq had shown 2 base substitutions in the same codon so that the actual amino-acid change(s) were impossible to infer (a ponatinib-resistant pt with a T315M mutation, 2 dasatinib-resistant pts with various combinations of F317I, F317C and/or F1317L, a dasatinib-resistant pt with 2 different nucleotide substitutions both leading to the V299L)...
DOI:
10.1182/blood-2018-99-117028
Trial ID:
Source:
Title:
Exploiting temporal collateral sensitivity in tumor clonal evolution
Excerpt:
...BCR-ABL1 V299L expectedly conferred resistance to dasatinib and bosutinib, we observed strong and robust sensitization to crizotinib, foretinib, cabozantinib, and vandetanib...
DOI:
https://dx.doi.org/10.1016%2Fj.cell.2016.01.045
